Indeed, targeting TNF-α in sarcoidosis is not a new approach: Infliximab, a readily available anti-TNF-α medication, has been studied in patients with glucocorticoid-refractory disease, with encouraging results. The gene discussed is TNF; the disease is sarcoidosis.